365 related articles for article (PubMed ID: 21345752)
1. Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?
Helfrich I; Schadendorf D
Mol Oncol; 2011 Apr; 5(2):137-49. PubMed ID: 21345752
[TBL] [Abstract][Full Text] [Related]
2. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.
Helfrich I; Scheffrahn I; Bartling S; Weis J; von Felbert V; Middleton M; Kato M; Ergün S; Augustin HG; Schadendorf D
J Exp Med; 2010 Mar; 207(3):491-503. PubMed ID: 20194633
[TBL] [Abstract][Full Text] [Related]
3. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy.
Gee MS; Procopio WN; Makonnen S; Feldman MD; Yeilding NM; Lee WM
Am J Pathol; 2003 Jan; 162(1):183-93. PubMed ID: 12507901
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis in malignant melanoma.
Felcht M; Thomas M
J Dtsch Dermatol Ges; 2015 Feb; 13(2):125-36. PubMed ID: 25631130
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies.
Basu B; Biswas S; Wrigley J; Sirohi B; Corrie P
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1583-98. PubMed ID: 19895243
[TBL] [Abstract][Full Text] [Related]
6. Vascular phenotype identification and anti-angiogenic treatment recommendation: A pseudo-multiscale mathematical model of angiogenesis.
Hutchinson LG; Gaffney EA; Maini PK; Wagg J; Phipps A; Byrne HM
J Theor Biol; 2016 Jun; 398():162-80. PubMed ID: 26987523
[TBL] [Abstract][Full Text] [Related]
7. Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
Mancuso MR; Davis R; Norberg SM; O'Brien S; Sennino B; Nakahara T; Yao VJ; Inai T; Brooks P; Freimark B; Shalinsky DR; Hu-Lowe DD; McDonald DM
J Clin Invest; 2006 Oct; 116(10):2610-21. PubMed ID: 17016557
[TBL] [Abstract][Full Text] [Related]
8. A role for VEGF as a negative regulator of pericyte function and vessel maturation.
Greenberg JI; Shields DJ; Barillas SG; Acevedo LM; Murphy E; Huang J; Scheppke L; Stockmann C; Johnson RS; Angle N; Cheresh DA
Nature; 2008 Dec; 456(7223):809-13. PubMed ID: 18997771
[TBL] [Abstract][Full Text] [Related]
9. The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels.
Iivanainen E; Lauttia S; Zhang N; Tvorogov D; Kulmala J; Grenman R; Salven P; Elenius K
Microvasc Res; 2009 Dec; 78(3):278-85. PubMed ID: 19596357
[TBL] [Abstract][Full Text] [Related]
10. Trends and Challenges in Tumor Anti-Angiogenic Therapies.
Jászai J; Schmidt MHH
Cells; 2019 Sep; 8(9):. PubMed ID: 31540455
[TBL] [Abstract][Full Text] [Related]
11. Screening assay for blood vessel maturation inhibitors.
Fu C; van der Zwan A; Gerber S; Van Den Berg S; No E; Wang WC; Sheibani N; Carducci MA; Kachhap S; Hammers HJ
Biochem Biophys Res Commun; 2013 Aug; 438(2):364-9. PubMed ID: 23892038
[TBL] [Abstract][Full Text] [Related]
12. Pericytes: a double-edged sword in cancer therapy.
Meng MB; Zaorsky NG; Deng L; Wang HH; Chao J; Zhao LJ; Yuan ZY; Ping W
Future Oncol; 2015; 11(1):169-79. PubMed ID: 25143028
[TBL] [Abstract][Full Text] [Related]
13. Pericytes and vessel maturation during tumor angiogenesis and metastasis.
Raza A; Franklin MJ; Dudek AZ
Am J Hematol; 2010 Aug; 85(8):593-8. PubMed ID: 20540157
[TBL] [Abstract][Full Text] [Related]
14. Normalization of the vasculature for treatment of cancer and other diseases.
Goel S; Duda DG; Xu L; Munn LL; Boucher Y; Fukumura D; Jain RK
Physiol Rev; 2011 Jul; 91(3):1071-121. PubMed ID: 21742796
[TBL] [Abstract][Full Text] [Related]
15. Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy.
Elebiyo TC; Rotimi D; Evbuomwan IO; Maimako RF; Iyobhebhe M; Ojo OA; Oluba OM; Adeyemi OS
Cancer Treat Res Commun; 2022; 32():100620. PubMed ID: 35964475
[TBL] [Abstract][Full Text] [Related]
16. LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways.
Chung SW; Bae SM; Lee M; Al-Hilal TA; Lee CK; Kim JK; Kim IS; Kim SY; Byun Y
Biomaterials; 2015 Jan; 37():271-8. PubMed ID: 25453957
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis in melanoma.
Mahabeleshwar GH; Byzova TV
Semin Oncol; 2007 Dec; 34(6):555-65. PubMed ID: 18083379
[TBL] [Abstract][Full Text] [Related]
18. Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy.
Ichikawa K; Watanabe Miyano S; Minoshima Y; Matsui J; Funahashi Y
Sci Rep; 2020 Feb; 10(1):2939. PubMed ID: 32076044
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenografts.
Gaustad JV; Simonsen TG; Andersen LMK; Rofstad EK
BMC Cancer; 2017 Jun; 17(1):411. PubMed ID: 28606060
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis, lymphangiogenesis, and melanoma metastasis.
Streit M; Detmar M
Oncogene; 2003 May; 22(20):3172-9. PubMed ID: 12789293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
